Imbria Pharmaceuticals
Series B in 2025
Imbria Pharmaceuticals, founded in 2018 and headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies targeting cardiometabolic disorders. The company focuses on understanding the underlying mechanisms of these diseases, particularly energetic impairment at the cellular level, to inform its therapeutic candidates. Imbria's pipeline aims to improve the lives of patients suffering from conditions such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction by restoring or enhancing cellular energy production.
Character Biosciences
Series B in 2025
Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health.
To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.
Perceive Pharma
Series A in 2025
Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.
Aviceda Therapeutics
Series C in 2025
Aviceda Therapeutics is a late-stage biotechnology company developing immunomodulators using glycobiology to target innate immune cells and treat chronic inflammation. Its cell-based high-throughput screening platform enables rapid discovery of ligands for various immune cells, with applications in eye diseases, fibrosis, neurology, and oncology.
Alentis Therapeutics
Series D in 2024
Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.
PrognomiQ
Series D in 2024
PrognomiQ is a technology company focused on transforming early disease detection and treatment through multi-omics data. It generates proteomic, genomic, and metabolomic data to provide insights into complex diseases and to improve patient outcomes. The company develops advanced test products that apply multi-omics data to detect cancers and other conditions earlier, complementing traditional diagnostics and supporting monitoring of disease recurrence. By integrating proteomic data with broader health data, PrognomiQ aims to enable clinicians to diagnose more accurately and tailor interventions, ultimately advancing preventive and precision medicine.
Orasis Pharmaceuticals
Series D in 2024
Founded in 2015, Orasis Pharmaceuticals specializes in developing corrective eye drops for treating presbyopia. Its lead product, CSF-1, improves near visual acuity by pupil modulation, eliminating the need for reading glasses.
Orasis Pharmaceuticals
Venture Round in 2024
Founded in 2015, Orasis Pharmaceuticals specializes in developing corrective eye drops for treating presbyopia. Its lead product, CSF-1, improves near visual acuity by pupil modulation, eliminating the need for reading glasses.
Superluminal Medicines
Series A in 2024
Superluminal Medicines is a biotechnology company specializing in generative biology and chemistry. It employs a unique platform that combines deep biological and chemical expertise, machine learning, and proprietary big data infrastructure to rapidly generate candidate-ready compounds for drug discovery and development. By integrating high-throughput experimental data with advanced algorithms, the company aims to accelerate the identification and optimization of novel drug candidates, improving efficiency and success rates in small molecule drug development compared to traditional methods.
Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By harnessing self-supervised learning and integrating diverse human multimodal data, the company aims to enhance the precision and effectiveness of immunotherapies. This approach enables the development of more personalized cancer treatments, contributing to the advancement of targeted therapies in oncology.
Imperative Care
Series E in 2024
Founded in 2015, Imperative Care specializes in developing innovative medical technologies aimed at improving stroke treatment. Its flagship products include the Large Distal Platform catheter for deeper reach and the ZOOM Aspiration System for clot removal. The company's mission is to enhance treatment speed and effectiveness, ultimately optimizing patient recovery.
InSightec
Private Equity Round in 2024
InSightec Ltd. is a pioneering company based in Tirat Carmel, Israel, specializing in non-invasive medical treatments through its Exablate platform, which employs MR guided focused ultrasound technology. Founded in 1999, InSightec develops and distributes systems that address various oncology and gynecology conditions, including the Exablate Neuro for personalized thalamotomy in movement disorders and pain management. The Exablate system has received multiple regulatory approvals, including CE marks and FDA approval, for treatments of symptomatic uterine fibroids, pain from bone metastases, and adenomyosis. The company provides comprehensive support services, including onsite clinical training and maintenance, to medical professionals using its technology in facilities across Israel and internationally. InSightec maintains a strategic partnership with Lantheus Holdings and has expanded its presence in Europe, Asia, and the Americas, earning recognition for its innovative contributions to the field of acoustic surgery.
Avava
Venture Round in 2024
Avava is a pioneering company specializing in precision skin therapy aimed at enhancing the quality of life for patients globally. It has developed advanced 3D laser treatment technology that focuses on rejuvenating skin color. This innovative technology specifically addresses conditions such as melasma and post-inflammatory hyperpigmentation, allowing healthcare providers to deliver effective tissue treatments to their patients. Through its commitment to improving skin health, Avava seeks to provide solutions that significantly benefit individuals facing various skin challenges.
PinkDx is a biotechnology company specializing in women's health. It develops molecular tests to improve diagnostic outcomes for women with vague gynecological cancer symptoms, offering alternatives to invasive procedures. This enables more comfortable and efficient resolution of health concerns, providing timely and positive impacts on patients' lives.
Protara Therapeutics
Post in 2024
Protara Therapeutics is a clinical-stage company focused on identifying and advancing transformative therapies for cancer and rare diseases. Its lead program, TARA-002, is an investigational cell therapy being developed for non-muscle invasive bladder cancer and lymphatic malformations, while IV choline chloride is an investigational phospholipid substrate replacement therapy for intestinal failure-associated liver disease. The company is based in New York, New York.
Clasp Therapeutics
Series A in 2024
Clasp Therapeutics develops precision oncology platforms to identify neoantigens from driver mutations in hard-to-treat cancers. Its technology enables the creation of targeted therapies that selectively bind to HLA-presented peptides, allowing for precise destruction of cancer cells across various tumor types.
Roshal Imaging Services
Venture Round in 2024
Roshal Imaging Services is a provider of on-site and portable diagnostic Vascular and General body (Ob/Gyne) ultrasound services. The company was founded in 2005 and is based in Katy, Texas, United States.
NextPoint Therapeutics
Series B in 2024
NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.
OnCusp Therapeutics
Series A in 2024
OnCusp Therapeutics is a biopharmaceutical company dedicated to accelerating oncology medication innovation globally. It focuses on translating preclinical drug candidates into clinical proof-of-concept stage and advancing them for rapid global early clinical development.
Lassen Therapeutics
Series B in 2023
Lassen Therapeutics is a biotechnology company focused on developing monoclonal antibodies as potential treatments for fibrosis, rare diseases, and oncology. Its lead candidate, LASN01, targets the IL-11 receptor alpha, a critical mediator in fibrosis and tumor microenvironment organization. By blocking IL-11, Lassen Therapeutics aims to offer a more effective treatment strategy compared to traditional approaches that focus on other factors, such as TGF-β and CTGF. The company's innovative biotherapeutics leverage advanced antibody technologies to address serious health conditions, ultimately improving the lives of patients suffering from these diseases.
RefleXion Medical
Venture Round in 2023
RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.
Sanguine
Debt Financing in 2023
Sanguine accelerates biomedical research by removing barriers to patient participation. It engages patients transparently, supports them respectfully, compensates them appropriately, aiming for better patient experiences and more impactful research biospecimens.
Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.
Rejuveron Life Sciences
Series B in 2023
Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.
Georgiamune
Series A in 2023
Georgiamune is an immunotherapy company that develops oncology-focused treatments. It advances next-generation immunotherapies and homeostatic therapies aimed at cancer and autoimmune diseases. The company's approach targets immune signaling pathways to reprogram the immune system and restore immune homeostasis, helping patients fight cancer and autoimmune conditions.
Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.
NextPoint Therapeutics
Series B in 2023
NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.
Spiral Therapeutics
Venture Round in 2023
Spiral Therapeutics, Inc. is a clinical-stage pharmaceutical company founded in 2016 and based in San Francisco, California. The company specializes in developing novel therapies for inner ear disorders, particularly focusing on acute and subacute hearing loss as well as balance disorders caused by neurodegenerative, inflammatory, or vascular issues. Spiral Therapeutics employs a unique platform that aims to deliver targeted drug therapies directly to the inner ear, optimizing treatment effectiveness by ensuring that the right medications are administered at the right location and for the appropriate duration. Through its innovative approach, the company seeks to provide patients with effective treatments for hearing loss and related conditions.
Perceive Biotherapeutics
Series B in 2023
Perceive Biotherapeutics is a biotechnology company focused on developing innovative ophthalmic therapeutics aimed at treating various eye diseases. The company leverages advanced protective biologies to create a diverse pipeline of therapeutic assets that target significant causes of irreversible blindness. By employing multiple therapeutic modalities, Perceive Biotherapeutics aims to provide medical professionals with effective solutions for preventing vision loss and enhancing patient outcomes in the field of ophthalmology.
Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.
Metagenomi
Series B in 2023
Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.
Sickbay
Debt Financing in 2022
Sickbay is a healthcare services company that specializes in patient monitoring and analytics. Founded in 1999, Sickbay offers a software platform designed to assist healthcare professionals by providing comprehensive access to patient data, including medical histories and real-time monitoring from various devices. Its solutions focus on automating documentation and improving alarm management, which helps reduce unnecessary alarm noise and ensures that care providers receive pertinent alerts. Additionally, Sickbay engages in the wholesale marketing of FDA-authorized nutritional supplements, aimed at supporting hospital professionals and medical staff in delivering informed, data-driven patient care.
Haystack Oncology
Series A in 2022
Haystack Oncology is an oncology company that specializes in advanced liquid biopsy diagnostic technology aimed at improving cancer treatment strategies and patient outcomes. The company utilizes state-of-the-art circulating tumor DNA detection methods to enhance the diagnosis of minimal residual disease, allowing for more informed therapy decision-making. By analyzing tumor-specific markers in blood samples, Haystack Oncology's technology provides high sensitivity for early detection of recurrent disease, thereby enabling healthcare teams to effectively manage cancer treatment. The company's innovative approach seeks to transform how cancer is monitored and treated, ultimately benefiting patients through improved diagnostic accuracy and treatment effectiveness.
Proto Axiom
Series A in 2022
Proto Axiom is an incubator based in Melbourne, Australia, established in 2021. The company focuses on enhancing the country's biotechnology sector by fostering the development of innovative drug and medical equipment technologies. Recognizing that Australia produces significant intellectual property in these fields but struggles with downstream commercialization, Proto Axiom aims to retain this valuable intellectual property within the country by developing preclinical expertise and supporting local ventures. Through its initiatives, the firm seeks to create job opportunities and bolster the domestic biotechnology landscape.
Fractyl Health
Series F in 2022
Fractyl Health Inc. is a medical technology company dedicated to developing innovative solutions for the treatment of metabolic diseases, particularly type 2 diabetes and obesity. The company specializes in a minimally invasive procedure known as Revita DMR, or duodenal mucosal resurfacing therapy, which rejuvenates the lining of the duodenum through hydrothermal ablation. This approach aims to remove excessive layers of the duodenal mucosa that accumulate due to unhealthy diets, thereby addressing the root causes of metabolic disorders. Founded in 2010 and based in Lexington, Massachusetts, Fractyl Health seeks to redefine the treatment landscape from chronic management to durable, disease-modifying therapies, ultimately enhancing patient health and reducing the burden on healthcare systems.
Cartography Biosciences
Series A in 2022
Cartography Biosciences specializes in developing precision cancer immunotherapies. It employs single-cell analysis to identify novel targets for Chimeric Antigen Receptor T-cell (CAR-T) therapies, aiming to enhance safety and efficacy.
Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.
Anagenex is a biotechnology company developing a novel platform for drug discovery. This platform focuses on challenging targets by combining machine learning with DNA-encoded libraries and proprietary AI models to accelerate small molecule drug discovery.
Sickbay
Venture Round in 2022
Sickbay is a healthcare services company that specializes in patient monitoring and analytics. Founded in 1999, Sickbay offers a software platform designed to assist healthcare professionals by providing comprehensive access to patient data, including medical histories and real-time monitoring from various devices. Its solutions focus on automating documentation and improving alarm management, which helps reduce unnecessary alarm noise and ensures that care providers receive pertinent alerts. Additionally, Sickbay engages in the wholesale marketing of FDA-authorized nutritional supplements, aimed at supporting hospital professionals and medical staff in delivering informed, data-driven patient care.
Character Biosciences
Series A in 2022
Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health.
To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.
Octant Bio
Series B in 2022
Octant Bio is a company focused on developing synthetic technology to enhance health and treat diseases. The firm employs synthetic biology, genome engineering, next-generation sequencing, and computational tools to measure the activity of thousands of receptor pathways in human cells simultaneously. This approach allows scientists to use machine learning methods to engineer small molecules that can interact with multiple receptors, offering new potential for treating complex diseases.
Pheast Therapeutics
Series A in 2022
Pheast Therapeutics is a cancer immunotherapy company developing macrophage-targeted therapies and innate immune checkpoint inhibitors to engage the body's innate immune response against cancer. The company focuses on agents that enhance macrophage phagocytosis and tumor cell elimination, including antibodies targeting CD24 to boost macrophage activity. Founded in 2020 and headquartered in Palo Alto, California, Pheast aims to offer innovative oncology treatments that complement existing therapies and improve patient outcomes.
Celsius Therapeutics
Series B in 2022
Celsius Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for patients suffering from cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a multidisciplinary approach, integrating the expertise of scientists, computational biologists, and clinicians. Celsius Therapeutics utilizes advanced techniques such as single-cell genomic analysis and machine learning to identify and develop innovative therapeutic solutions. By leveraging these cutting-edge technologies, the company aims to create life-changing medicines that address unmet medical needs.
Affini-T Therapeutics
Venture Round in 2022
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-cell therapies designed to eradicate tumors.
PrognomiQ
Venture Round in 2022
PrognomiQ is a technology company focused on transforming early disease detection and treatment through multi-omics data. It generates proteomic, genomic, and metabolomic data to provide insights into complex diseases and to improve patient outcomes. The company develops advanced test products that apply multi-omics data to detect cancers and other conditions earlier, complementing traditional diagnostics and supporting monitoring of disease recurrence. By integrating proteomic data with broader health data, PrognomiQ aims to enable clinicians to diagnose more accurately and tailor interventions, ultimately advancing preventive and precision medicine.
RefleXion Medical
Venture Round in 2022
RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.
Sherlock Biosciences
Series B in 2022
Sherlock Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative molecular diagnostic solutions. The company utilizes advanced engineering biology tools, such as CRISPR and synthetic biology, to create diagnostic platforms capable of delivering accurate and rapid results. Its notable technologies include SHERLOCK, a method for detecting and quantifying specific genetic sequences, and INSPECTR, which is designed for versatile, easy-to-use diagnostics. Sherlock Biosciences aims to serve various applications, including precision oncology, infectious disease identification, food safety, at-home testing, and general disease detection. Founded in 2018, the company is committed to providing affordable diagnostics suitable for diverse settings, including those with low-resource environments.
Satellite Bio
Series A in 2022
Satellite Bio develops cell therapies and regenerative medicine approaches, spanning cell biology, tissue engineering, and synthetic biology. The company focuses on proprietary, off-the-shelf implantable satellite organs that function as living therapeutic systems to replace or augment critical organ functions in patients with serious diseases, enabling medical professionals to address conditions arising from genetic and environmental factors. Its platform supports the development of modular, scalable therapies aimed at treating complex diseases and transforming patient outcomes.
Septerna is a biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). It operates a proprietary Native Complex Platform to accelerate GPCR drug discovery and aims to deliver therapies across endocrinology, immunology and inflammation, and metabolic diseases. The company is advancing a GPCR-focused pipeline with candidates such as SEP-786 (PTH1R) and SEP-631 (MRGPRX2), along with programs targeting TSHR, GLP-1R, GIPR, and GCGR, with the goal of translating GPCR biology into orally available medicines that address unmet patient needs.
DNA Script
Series C in 2022
DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.
Hyperfine is a pioneering medical device company that developed Swoop®, the world's first FDA-cleared point-of-care MRI system. Designed to enhance patient access to critical care, Swoop produces high-quality images rapidly and at a lower cost than conventional MRIs, enabling clinicians to diagnose and treat patients swiftly in various clinical settings.
Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.
Bayesian Health
Venture Round in 2021
Founded in 2016, Bayesian Health offers an AI-driven platform that integrates with hospital EMR systems. It provides real-time, actionable insights to healthcare teams by analyzing multi-layered clinical data sets, enabling timely decisions and improving patient care efficiency.
Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.
Enveda Biosciences
Series A in 2021
Enveda is a biotechnology company that uses AI-powered tools to explore and characterize molecules from living organisms. It aims to accelerate drug discovery by developing a comprehensive database of chemical biodiversity.
Volastra
Seed Round in 2021
Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.
Immunai develops an AI-based immune profiling platform for drug discovery, diagnosis, and treatment. It offers multi-omic single-cell genomics with machine learning algorithms, enabling high-resolution profiling of the immune system at scale. Immunai partners with academic institutions and biopharmaceutical companies to accelerate research and development in immunology.
Cambrian BioPharma
Series B in 2021
Cambrian BioPharma specializes in developing innovative therapeutics aimed at extending healthspan, the period of life spent in good health. As a Distributed Development Company (DisCo), it focuses on advancing scientific breakthroughs targeting biological drivers of aging, initially treating specific diseases and later deploying these interventions preventatively to enhance overall quality of life.
Paige is a company focused on computational pathology, developing an AI-powered platform that assists pathologists in diagnosing cancer and guiding treatment decisions. The platform integrates deep learning models, including convolutional and recurrent neural networks and generative methods, to enable rapid diagnostic stratification and cancer detection, with emphasis on breast and prostate cancers. Designed to improve diagnostic confidence and workflow efficiency, Paige's lightweight solution aims to minimize IT burden while ensuring patient safety and data privacy. Paige holds a FDA Breakthrough designation for computational pathology products, highlighting its role in advancing pathology through automated analysis of tissue slides. The company targets clinical researchers and pathology teams with tools that deliver insights to support precise diagnoses and better patient outcomes.
Sensei Biotherapeutics
Series B in 2021
Sensei Biotherapeutics is a clinical-stage biotechnology company developing next-generation cancer immunotherapies. It focuses on novel biologics that modulate the immune system to treat cancers with unmet need, using its ImmunoPhage discovery platform to study the tumor microenvironment and identify differentiated mechanisms that engage both innate and adaptive immunity. The company pursues a Tumor Microenvironment Activated Biologics TMAb platform to selectively disable immunosuppressive signals or activate immunostimulatory signals within the tumor microenvironment. Headquartered in Gaithersburg, Maryland with an office in Boston, Massachusetts, Sensei Biotherapeutics has four investigational product candidates in development: SNS-101, SNS-102, SNS-103, and SNS-201.
Faze Medicines
Series A in 2020
Faze Medicines is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. It focuses on developing small molecule drugs targeting key drivers of disease pathology, with initial therapeutic areas including amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). The company employs advanced screening and proteomics techniques to define condensate interaction networks, aiming to pioneer innovative therapeutics based on biomolecular condensates. Through its research, Faze Medicines seeks to provide effective treatments for complex diseases such as ALS and frontotemporal dementia (FTD).
ATAI Life Sciences
Series C in 2020
ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.
Glympse Bio
Series B in 2020
Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.
GlycoEra is a biotechnology company focused on developing novel therapeutics by harnessing the power of glycan-mediated biology.